Most cited papers from ImCyse (Belgium)

ImCyse (Belgium)

What are the most cited papers from ImCyse (Belgium)?

The most cited paper from ImCyse (Belgium) is "First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes" (Jean Van Rampelbergh, Peter Achenbach, Richard David Leslie et al., 2023), with 28 citations. Next come "A future of AI-driven personalized care for people with multiple sclerosis" (24) and "Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model" (22).

Published FieldAccess

Showing 10 of 10 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes Jean Van Rampelbergh, Peter Achenbach, Richard David Leslie et al. · BMC Medicine Open access	24 May 2023	28
2	A future of AI-driven personalized care for people with multiple sclerosis Jelle Praet, Lina Anderhalten, Giancarlo Comi et al. · Frontiers in Immunology Open access	19 Aug 2024	24
3	Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model Elin Malek Abrahimians, Luc Vander Elst, Vincent A. Carlier et al. · Frontiers in Immunology Open access	2 Mar 2016	22
4	First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers Jean Van Rampelbergh, Peter Achenbach, Richard David Leslie et al. · BMC Medicine Open access	21 Jun 2024	17
5	T cell response to FVIII Marc G Jacquemin, Jean‐Marie Saint‐Remy · Cellular Immunology	26 Sep 2015	13
6	MHC Class II-Restricted Epitopes Containing an Oxidoreductase Activity Prompt CD4+ T Cells with Apoptosis-Inducing Properties Elin Malek Abrahimians, Vincent A. Carlier, Luc Vander Elst et al. · Frontiers in Immunology Open access	2 Sep 2015	12
7	Suppression of Immune Response to Adenovirus Serotype 5 Vector by Immunization with Peptides Containing an MHC Class II Epitope and a Thio-Oxidoreductase Motif Wei Miao, Roxana Roohi Ahangarani, Vincent A. Carlier et al. · Human Gene Therapy	29 Dec 2015	4
8	THU0032 MODIFIED PEPTIDES AS A NOVEL IMMUNOTHERAPY FOR RHEUMATOID ARTHRITIS Eleni Araklioti, L A Herman, Ngoc Quynh Nhu Nguyen et al. · Annals of the Rheumatic Diseases Open access	Jun 2020	3
9	RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis Jelle Praet, Lina Anderhalten, Giancarlo Comi et al. · Frontiers in Neurology Open access	16 May 2025	1
10	Technology transfer and process development for an autologous T cell therapy against multiple sclerosis Agnieszka Legutko, Vincent A. Carlier, Ainhoa Gaztelumendi et al. · Cytotherapy	27 Apr 2015	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.